Table 5: Proportions of patients who experienced decreases in platelet counts during RA treatment in clinical .

% of ≤6 months>6 monthsClinical sequelae
Grade 3 or 4Grade 3 or 4

Conventional synthetic

Methotrexate0%1.3% [61, 67, 95]N/AN/A

Leflunomide0% [61]0%[96]N/A

Biologic

Adalimumab0.2%N/AN/A

InfliximabN/A0%[96]N/A

Golimumab≥1 abnormal value: 0.2%N/AN/A

Tocilizumab0.2% [87]<1.0% [27]One serious bleeding event of hemorrhagic stomatitis occurred in a patient with grade 4 thrombocytopenia [27]

RituximabN/AN/AN/A

AbataceptN/AN/AN/A

Anakinra0% [94]0% [94]N/A

DMARD, disease-modifying antirheumatic drug; N/A, not available; RA, rheumatoid arthritis; grades were defined as follows: grade 2, 50,000 to <75,000 cells/mm3; grade 3, 25,000 to <50,000 cells/mm3; grade 4, <25,000 cells/mm3. are the proportions of patients experiencing grade 3 or 4 platelet counts except where noted. data were available for sulfasalazine, hydroxychloroquine/chloroquine, certolizumab, etanercept, or tofacitinib. received leflunomide plus infliximab. medical letter (personal communication), data on file.